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A B S T R A C T
The objective of this study was to assess the clinical utility of the AUSDRISK tool for determining risk of Type 2
diabetes mellitus (T2DM). In this secondary analysis from the HealthTrack study, the AUSDRISK tool was ap-
plied to data from overweight/obese volunteers completing a lifestyle intervention trial. Participants were vo-
lunteer residents of the Illawarra region recruited in 2014–2015. From 377 trial participants (BMI 25–40 kg/m2,
25–54 yr), 161 provided data required for measurement of AUSDRISK, collected at 0 and 12months. They had
been randomised to one of two lifestyle interventions (± a healthy food sample, 30 g walnuts/day, I and IW)
delivered by dietitians, or a control intervention (C) delivered by nurse practitioners. HbA1c measures were
considered for comparison. At baseline the AUSDRISK score indicated n=83 (51.5%) were at high risk of T2DM
within 5 years (≥12 points). After 12months the proportion scored as high risk significantly decreased in the IW
group (51.5% vs 33.3%; p=0.005), but not I (51.2% vs 39.0%; p=0.063) or C group (51.9% vs 38.9%;
p=0.065). By comparison, HbA1c measures indicated high risk in n=24 (17%) of 139 participants at baseline
and borderline non-significant changes over time in the randomised groups. In conclusion, the AUSDRISK tool
has reasonable clinical utility in identifying T2DM risk in clinical samples of overweight/obese individuals.
1. Introduction
The global economic burden of type 1 and type 2 diabetes in 2015
was US$1·31 trillion (95% CI 1·28–1·36) or 1·8% (95% CI 1·8–1·9) of
global gross domestic product (Bommer et al., 2017). Obesity is a sig-
nificant aetiological cause of Type 2 Diabetes Mellitus (T2DM); being
overweight with substantial abdominal fat, or obese account for ap-
proximately 80–90% of all T2DM (Astrup and Finer, 2000). The relative
risk for T2DM among women who gain 5.0 to 7.9 kg was 1.9 and those
that gained 8.0 to 10.9 kg was 2.7 (Colditz et al., 1995). Clinical trials
have demonstrated that as little as 5% weight loss is sufficient to pre-
vent most obese subjects with impaired glucose tolerance developing
T2DM (Colditz et al., 1995; Hamman et al., 2006; Delahanty et al.,
2014). The rapid increase in obesity prevalence indicates an epidemic
and reversing the scale would reduce the prevalence of T2DM. The
obesity rate in Australia has tripled in the last three decades with one in
four Australians considered obese (Body Mass Index (BMI) > 30 kg/
m2) (Buchmueller and Johar, 2015). The impact on healthcare
expenditure is substantial. It has been estimated that, compared to a
person of normal weight, a person with a BMI between 30 and 35 kg/m2
has 19% higher healthcare costs, and a person with BMI > 35 kg/m2
has a 51% higher healthcare expenditure (Buchmueller and Johar,
2015). Early intervention is key to the prevention of chronic disease. It
has been well documented that multi-disciplinary lifestyle interventions
integrating nutrition, exercise and psychological support produces the
most significant and sustained results for weight loss (NHMRC, 2013).
Determining which patients are at greatest risk to target for lifestyle
intervention is challenging for clinicians. Some overweight and obese
people may be “metabolically healthy”, in that they do not present with
dyslipidemia, glucose perturbations and lack cardiovascular disease
symptoms (Phillips, 2016). General Practitioners (GPs) need a simple
tool to screen overweight/obese patients to identify those at greatest
risk of T2DM and refer them for lifestyle intervention before medical
intervention is required.
There are a number of methods to assess T2DM risk, and they differ
in sensitivity and specificity within various populations. The gold
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standard to assess insulin sensitivity is the Euglycaemic clamp, which is
invasive and not appropriate at a population level. The oral glucose
tolerance test lacks specificity as 40% of incident diabetes arises in
people who had a normal glucose tolerance 3–5 years earlier (Unwin
et al., 2002). The Homeostatic Model Assessment (HOMA) requires the
measurement of fasting glucose and insulin, but insulin is an expensive
and non-routine test. HbA1c reflects average glucose levels over the
preceding weeks and is used to routinely diagnose T2DM and detect
individuals at risk (American Diabetes Association, 2013). The Aus-
tralian Type 2 Diabetes Risk Assessment Tool (AUSDRISK) (Chen et al.,
2010) has been developed for use within an Australian population and
incorporates ten different medical, lifestyle and demographic variables
to determine 5 year T2DM risk. The AUSDRISK tool was introduced in
July 2008 by the Australian Government Department of Health and
Ageing and attracts a Medicare rebate for eligible patients (Australian
Government of Health and Ageing, 2008).
The utility of the AUSDRISK tool in clinical practice has not been
fully explored and clinical trials for obesity management provide a
useful opportunity. For example, the HealthTrack study incorporated
the services of all three allied health disciplines (dietetics, exercise
physiology, psychology) into a streamlined lifestyle intervention for an
overweight/obese clinical cohort and compared effects with usual care.
One experimental group received the interdisciplinary intervention,
another received the interdisciplinary intervention plus a healthy food
sample (30 g walnuts/day), and both reported a significant reduction in
weight over 12months compared to control participants (Tapsell et al.,
2017).
In this secondary analysis of data from HealthTrack we measured
T2DM risk by the AUSDRISK tool to investigate its clinical utility to
measure prevalence and change in an “at risk” population. The aim of
this exploratory study was to assess the change in T2DM risk in an
overweight/obese clinical sample undergoing a lifestyle intervention.
2. Subjects
The subjects of this analysis were HealthTrack study participants
described previously (Tapsell et al., 2015). In summary they were vo-
lunteer residents of the Illawarra region, aged 25–54 years, with a BMI
25–40 kg/m2, and randomly assigned to standard care (C), inter-
disciplinary intervention (I), or interdisciplinary intervention +
healthy food sample (30 g walnuts/day) (IW) for 12months. C partici-
pants received general advice on diet and exercise from a nurse prac-
titioner and a follow up phone call. I and IW participants received this
advice from an Accredited Practising Dietitian (APD) discussing in-
dividualised changes in specific food choices and providing advice on
physical activity with support from an Exercise Physiologist. They also
received scripted motivational telephone calls from trained health
coaches.
3. Materials and methods
This study involved the application of the AUSDRISK tool
(Australian Government of Health and Ageing, 2008) to data made
available from the HealthTrack study. Information required was age,
sex, ethnicity, parental history of diabetes, history of high blood glu-
cose, antihypertensive use, smoking, physical inactivity, waist cir-
cumference and fruit/vegetable consumption. The tool is available on
line (www.health.gov.au/internet/main/publishing.nsf/Content/
diabetesRiskAssessmentTool). The sensitivity and specificity of the
AUSDRISK tool has been reported as 74.0% and 67.7%, respectively for
a score of> 21%, with a positive predictive value (PPV) of 12.7%
(Australian Government of Health and Ageing, 2008).
Full details of the HealthTrack study protocol and results are re-
ported elsewhere (Tapsell et al., 2017; Tapsell et al., 2015). Briefly, a
population-based survey collected self-reported familial, medical and
pharmacological history (completed at screening and repeated at the
12month follow-up visit). Dietary intake was assessed using a diet
history interview (Martin et al., 2003) and physical activity using the
International Physical Activity Questionnaire (IPAQ) (Craig et al.,
2003) and via a pedometer (Yamax Digiwalker SW200, Pedometers
Australia) worn for a four day period every quarter. Waist cir-
cumference was measured at baseline and 12month visits by trained
personnel using standard protocols.
3.1. Statistical analysis
Data was available for this analysis from the HealthTrack study at
baseline and 12months. After applying the AUSDRISK tool participants
were categorised according to the following criteria:< 12 points= not
at high risk, and 12+ points= high risk of developing T2DM.
Statistical analysis was conducted using SPSS (version 21.0, IBM
Corp, Chicago IL, 2012). The categorised scores were compared be-
tween treatment groups at baseline and 12months using McNemar's
test for nominal data. The AUSDRISK scores for the three randomised
groups over time was log transformed and compared using mixed
measures repeated ANOVA.
For comparative purposes, data on HbA1c levels were also assessed
as a proxy for standard care. A HbA1c level of> 5.7% or taking gly-
caemic medication was considered at risk of T2DM. The HbA1c (%) was
also compared between treatment groups over time (baseline and
12months) using a mixed measures repeated ANOVA. The HbA1c ca-
tegorised data was compared between treatment groups at baseline and
12months using McNemar's test for nominal data.
4. Results
Characteristics of study participants at baseline for both the full
study sample (n=377) and participants included in this analysis
Table 1
Baseline demographics for original study sample (n=377), and AUSDRISK analysis sample (n=161).
Intervention+walnut Intervention Control
Original study sample (n=377)
N 126 125 126
Gender (% female) 74.6 73.6 73
Age (years), mean ± standard deviation 42.1 ± 8.7 43.9 ± 7.9 43.8 ± 7.5
BMI (kg/m2), mean ± standard deviation 32.6 ± 4.3 32.6 ± 4.3 32.5 ± 4.1
HbA1c (%), median (interquartile range) 5.1 (4.9–5.4) 5.2 (4.9–5.4) 5.2 (5.0–5.5)
AUSDRISK analysis sample (n=161)
N 66 41 54
Gender (% female) 65.2 65.9 70.4
Age (years), mean ± standard deviation 42.3 ± 8.8 45.1 ± 7.9 44.4 ± 7.6
BMI (kg/m2), mean ± standard deviation 32.2 ± 4.0 31.5 ± 4.1 31.6 ± 4.2
HbA1c (%), median (interquartile range) 5.2 (5.0–5.4) 5.1 (4.9–5.4) 5.2 (4.9–5.5)
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(n=161) are presented in Table 1. There were no significant differ-
ences in baseline characteristics between treatment groups (data not
shown).
The AUSDRISK scores were calculated at baseline and 12months for
the HealthTrack cohort and the data for each treatment arm are out-
lined in Table 2. AUSDRISK data was available at both time points on
161 participants. Across all randomised groups, 83 out of the 161
completers (51.5%) were considered at high risk of developing T2DM
within the next 5 years at baseline. When comparing change in AUS-
DRISK continuous data between randomised groups there was a sig-
nificant reduction in scores over time (F(1,158)= 65.2, p < 0.005) but
no difference between treatment groups (F(2,158)= 0.048, p=0.95).
The change in the continuous measures of HbA1c (%) over time are
summarised in Table 1. HbA1c data was only available at both time
points on 139 participants. Across all randomised groups, 24 out of the
139 completers (17%) were considered at high risk of developing T2DM
based on HbA1c criteria at baseline. There were no statistically sig-
nificant differences between baseline and 12months or between treat-
ment groups in HbA1c levels (F(3.2,221)= 0.67, p=0.58).
When the data was analysed by categorising the data as “high risk”
or “not at high risk”, the proportion of participants in the IW group with
an AUSDRISK score≥ 12 was 51.5% (n=34) at baseline and 33.3%
(n=22) at 12months, which was a significant reduction over time
(p=0.005) (Fig. 1). The proportion of I and C groups with an AUSD-
RISK score≥ 12 points was lower after the 12month intervention, but
this was borderline non-significant (I 51.2 (n=21) vs 39.0% (n=16);
p=0.063 and C 51.9 (n=28) vs 38.9% (n=21); p=0.065) (Fig. 2).
The proportion of participants categorised as “at risk” of T2DM
using the HbA1c > 5.7% criteria are summarised in Fig. 2. The pro-
portion of HbA1c considered “at risk” of T2DM was non-significantly
reduced between baseline and 12months (IW 20 (n=12) vs 12%
(n=7), p=0.06; I 11 (n=4) vs 11% (n=4), p=0.99; C 18 (n=8)
vs 7% (n=3), p=0.06) in the randomised arms.
5. Discussion
This secondary analysis of data from the HealthTrack trial examined
the utility of the AUSDRISK tool (and by comparison the routinely
measured HbA1c) in an overweight/obese population undertaking
lifestyle intervention. The AUSDRISK tool identified participants at high
risk of developing T2DM within 5 years. The clinical utility of the tool
was evident as it showed a significant reduction in the proportion at
high risk of T2DM after 12months intervention in the IW group, con-
sistent with the greater weight loss observed in this group reported in
the primary analysis of the trial (Tapsell et al., 2017).
Identification of individuals at increased risk of T2DM is vital in
ensuring targeted treatment and management to reduce the global
disease burden of diabetes. Overweight and obesity is associated with
insulin resistance, and reducing weight and increasing exercise can
improve insulin sensitivity (Espeland, 2007; Esposito et al., 2003).
There is a need to identify which overweight/obese patients are at
greatest risk of developing T2DM and which tool general practitioners
could best use to identify these patients. Not all overweight or obese
people will go on to develop chronic disease in the immediate future. In
fact “metabolically healthy obesity” is a recent phenotype described in
the literature and may account for between 10 and 40% of obese people
Table 2
AUSDRISK and HbA1c (%) at baseline and 12months in the 3 randomised arms of the HealthTrack study conducted on Illawarra Residents recruited in 2014 and
2015.








AUSDRISK score Baseline 11.85 4.74 12.10 5.86 11.52 4.46
12months⁎ 9.61 5.11 9.95 8.00 10.11 4.67








HbA1c % Baseline 5.2 4.9–5.5 5.1 4.9–5.4 5.1 4.9–5.5
12months 5.1 4.9–5.4 5.1 4.9–5.4 5.2 5.0–5.4
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Fig. 1. Proportion of participants with an AUSDRISK score≥ 12 in randomised
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Fig. 2. Proportion of participants with a HbA1c > 5.7% or on glycaemic
medication in randomised arms of the HealthTrack clinical trial.
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(Phillips, 2016).
The problem that arises is there are multiple tools to assess risk of
T2DM in an individual. The important aspects for screening tools at a
population level are low cost, non-invasive and easy to access. HbA1c is
considered the standard method to assess insulin resistance and is
routinely measured, non-fasting, and inexpensive. It has been suggested
that HbA1c can predict future onset of diabetes better then fasting
blood glucose (Bonora and Tuomilehto, 2011). However, others suggest
HbA1c is less sensitive, stating that HbA1c 6–6.4% missed 90% of in-
dividuals at risk of diabetes and 5.7–6.4% missed 75% (Lorenzo et al.,
2010). In the HealthTrack cohort only 17.3% of participants had
HbA1c > 5.7% or taking glycaemic medication at baseline. The pro-
portion of participants identified as “at risk” using HbA1c was sub-
stantially lower than those identified using the AUSDRISK tool (51.6%).
This may infer that the AUSDRISK score is a better tool to predict 5 year
risk, and HbA1c may not be associated with a long-term forecast, but
more importantly an assessment of current T2DM status.
The AUSDRISK tool was developed in 2008 by the Australian
Government Department of Health and Ageing, and was validated in
2010 using the AusDiab study population (Chen et al., 2010). It was
translated into a “patient-friendly” version by the Baker IDI Heart and
Diabetes Institute (http://www.health.gov.au/internet/main/
publishing.nsf/Content/diabetesRiskAssessmentTool). A systematic lit-
erature review identified 65 T2DM risk assessment tools worldwide,
with only 10 reporting on their use as a screening tool (Dhippayom
et al., 2014). Since AUSDRISK was validated there has only been two
further studies assessing the use of this tool in practice. Pasco et al.
(2010) applied AUSDRISK to a cohort of women>25 years old
(n=1494), and reported that while 6.6% had ≥12 points but only
n=28 (1.9%) developed diabetes during the 3 year follow-up (Pasco
et al., 2010). This proportion at risk of T2DM is much lower than in our
study however our cohort were all overweight or obese and included
males and females. The publication by Pasco (2010) was a letter to the
editor so no other data were provided on lifestyle or weight, making it
difficult to compare results. Aguiar et al. (2015) applied AUSDRISK to
101 Australian men aged 18–65 years, with BMI 25–40 kg/m2 and no
diabetes (Aguiar et al., 2015); 40% scored 12-15points, 24% scored
16–19 points, 37% scored ≥20 points (i.e. 100% considered “at risk”).
These results are higher than assessed for our clinical cohort (51%
scored> 12 points). This difference may be due to our population
being a mixed population of men (26%) and women (74%), as men
have a greater incidence of insulin resistance than women. According to
the AUSDRISK report an individual with an AUSDRISK score between
12 and 15 points has a 7% risk of developing T2DM, and between 16
and 19 points has a 14% risk, whereas an individual with an AUSDRISK
score≥ 20 points has a 33% chance of developing T2DM (Australian
Government Department of Health and Ageing, 2010).
In Australia, the AUSDRISK tool attracts a Medicare rebate in pa-
tients aged 40–49 years who are at high risk of developing T2DM.
However, only about 23% of general practitioners are aware of AUS-
DRISK and only 14% have actually used AUSDRISK (Wong et al., 2011).
The utility of the AUSDRISK tool has now been demonstrated in over-
weight/obese participants in the HealthTrack study. There is value in
referring “at risk” patients for multi-disciplinary lifestyle intervention
before the onset of chronic disease. This analysis also reflected the
primary weight loss finding of HealthTrack (Tapsell et al., 2017), where
lifestyle intervention, whether nurse-led, or Accredited Practising Die-
titian (APD) delivered with health coaching, can lead to reduced risk of
T2DM over 12months. However, an inter-disciplinary approach lead by
an APD along with the provision of a healthy food (30 g daily walnuts)
may reduce T2DM risk significantly more than both a healthy lifestyle
intervention alone or usual care.
The improvement in diabetes risk observed in the walnut lifestyle
intervention arm may simply reflect the greater weight loss in this
group, but the types of foods consumed may be implicated. The addi-
tion of a healthy supplement into a lifestyle intervention providing
additional beneficial affects has been demonstrated previously (Salas-
Salvadó et al., 2008). Regular consumption of nuts has consistently
shown to be associated with a reduced risk of cardiovascular disease
(Kris-Etherton, 2014), however evidence of the relationship between
nuts and T2DM has been mixed (Zhou et al., 2014). Compared with
most nuts, which contain monounsaturated fatty acids, walnuts are a
rich source of polyunsaturated fatty acids, particularly Ω3 fatty acid, α
linolenic acid and Ω6 linoleic acid. Walnuts also provide several
bioactive constituents that may exert anti-inflammatory effects, such as
antioxidants (Kris-Etherton, 2014). Therefore this finding that the
walnut supplemented group reduced T2DM risk significantly is not
surprising, and it is supported by a recent large scale intervention in-
volving the Mediterranean diet (Salas-Salvadó et al., 2008), which in-
cluded greater consumption of nuts (50% of which were walnuts), fish
and oils.
This study was limited primarily because it was a secondary analysis
of trial data and so was not powered to detect significant differences in
these endpoints. Additionally, the withdrawal rate over the 12months
of the lifestyle clinical trial was high, with only 161 participants pro-
viding the data required to calculate AUSDRISK at 12months from an
original 377 randomised. Power statistics could not be calculated as it
was a secondary analysis of all available data. In addition, the use of
different sample sizes between groups and between measurements re-
duces the sensitivity of these analyses. Even with those limitations we
were able to observe a statistically significant reduction in T2DM risk in
the walnut intervention. The lower number of participants in the HbA1c
analyses may account for the non-significant findings. Additionally, the
statistically significant change in AUSRISK in the IW group may be an
artefact of the higher weight loss and greater vegetable consumption,
factors included in the AUSDRISK model. However, improving these
factors is also known clinically to reduce the incidence of T2DM, so the
results are to be expected. Further prospective studies measuring
AUSDRISK and HbA1c that include a 5 year follow-up would be re-
quired to confirm our findings.
It is important to recognise that this exploratory research considered
the use of the AUSDRISK tool in a particular trial context, given that the
trial reflected a clinical setting. Nonetheless we are unable to generalise
beyond this context. Rather we are mobilising knowledge that suggests
value in the AUSDRISK tool as a resource that goes beyond observations
of HbA1c and draws attention to important lifestyle factors amenable to
change. Translation of these findings to changes in clinical practice
requires further exploration, which should consider strategies to
translate this knowledge within the confines of the current health
system, while also acknowledging the inherent complexity of the
system (Holmes et al., 2017).
The AUSDRISK tool was able to identify a reduction in T2DM risk
and differentiate between treatment groups in overweight/obese par-
ticipants attending a lifestyle intervention over 12months. Applying
the AUSDRISK tool to calculate T2DM 5 year risk in overweight and
obese people and implementing lifestyle change, may reduce the
chronic disease burden of the obesity epidemic.
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